Regulatory News:

Intrasense (Paris:ALINS) (FR0011179886 – ALINS), a global leader in multimodal medical imaging software, announces the signature of a master agreement with RadCore Labs, a leading imaging CRO in the United States.

Imaging CROs specialize in quantitative medical image analysis in clinical trials for the pharmaceutical and biotech industries thus providing their customers with a reliable assessment of response to treatments.

Through this master agreement, all RadCore Labs studies requiring advanced visualization and imaging biomarkers measurements will now be performed using the Myrian® platform developed by Intrasense.

Myrian® has indeed been selected by the American CRO for its advanced multimodality functions dedicated to oncology as well as its broad clinical coverage in other therapeutic areas. Myrian®’s advanced 3D quantification tools and outstanding ergonomics have also been key decisive factors.

Myrian® is deployed on a server as a thin client application, thus allowing both local and remote readers to review and process images anytime and anywhere. Along with a seamless integration into the CRO’s cloud PACS solution, this generates substantial productivity gains and higher flexibility. The streamlined image reading workflow results in better quality, reproducible assessments and higher customer satisfaction.

Christian Teague, Co-Founder, Chief Core Lab Administrator and Director of Business Development and Strategies at RadCore Labs is very enthusiastic about this partnership and the use of Myrian®: “Its seamless integration in our workflow and its ergonomics have allowed a very short learning curve and increased productivity. Thanks to Myrian®, we get automated, standardized and reliable results. We can therefore optimize our trials and execute them more efficiently than ever before. Myrian® will help us develop our business and our service offering.”

“The signature of this agreement with RadCore Labs is very significant for Intrasense”, comments Patrick Mayette, Intrasense CEO. “Indeed, RadCore Labs is a fast growing imaging CRO in the United States, the largest market for clinical trials. This collaboration contributes in developing our presence in the US and promotes Myrian® as the reference platform for image-based clinical studies.”

About Radcore Labs:

RadCore Labs is a leading supplier of quality, value, and expertise in the arena of imaging solutions for drug, biotechnology, and medical device clinical trials. Utilizing a vast array of highly trained and qualified subspecialty radiologists and cardiologists, the company strives to achieve the highest level of quality in their core competency. RadCore Labs supports trials with imaging endpoints requiring reliable quantitative and qualitative endpoints that are utilized for medical drug and device evaluation. The company provides comprehensive data management, quality control infrastructure, image analysis, and detailed solutions to scientific questions for clinical trials. RadCore Labs is up to date with any new FDA guidelines, regulatory changes, data submission modifications, and bureaucratic oversight and ensures FDA compliance in order to make certain the trial does not get stalled or misdirected.

For more information about RadCore Labs, please visit www.radcorelabs.com.

About Intrasense:

Created in 2004 with an innovative technology of tissues detection in CT scan, Intrasense designs, develops and markets Myrian®, a unique, vendor-neutral software suite for the visualization and advanced processing of multimodal medical images such as MRI, CT scans, PET, X-rays, and more. Developed with leading academic and scientific partners, Myrian® combines and uses all of the various medical images to extract information vital to the patient's care, to evaluate treatment efficiency and to assess drug candidates in oncology and other pathologies. With more than 700 client sites around the world, Myrian® has been certified as a "medical device" in over 40 countries including the United States (FDA), Europe (CE) and Asia. Intrasense SA is listed on the Alternext (FR0011179886 - ALINS). The company employs 70 people, including 25 dedicated in R&D. Labelled “innovative company” by Oseo, Intrasense has invested over 9 M€ in R&D since its creation.

For more about Intrasense, please visit www.intrasense.fr and follow us on LinkedIn.